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Trypanosoma cruzi, the agent of Chagas’ dis-
ease, is an obligate intracellular parasite that
invades various organs including several cell
types in the nervous system that express the
Trk receptor tyrosine kinase. Activation of Trk
is a major cell-survival and repair mechanism,
and parasites could use Trks to invade cells
as a strategy to protect their habitat and pro-
long parasitism of vertebrate hosts. We show
that T. cruzi binds to TrkA specifically and acti-
vates TrkA-dependent survival mechanisms.
This interaction facilitates parasite adherence
and promotes efficient invasion of neuronal, ep-
ithelial, and phagocytic cells via a process that
requires TrkA kinase activity. Diffusible TrkA
and TrkA-blocking agents neutralized infection
in cellular and animal models of acute Chagas’
disease, suggesting cellular receptors as thera-
peutic targets against parasitic diseases. Thus,
TrkA, the nerve growth factor receptor com-
monly associated with neural survival and pro-
tection, may also underlie clinical progression
of an important human parasitic disease.
INTRODUCTION
The receptor tyrosine kinases (RTK) TrkA, TrkB, and TrkC
are widely expressed in peripheral (PNS) and central
(CNS) nervous systems, where they primarily regulate sur-
vival and proliferation of cells (Bibel and Barde, 2000;
Huang and Reichardt, 2003). Trks are also expressed on
dendritic cells, lymphocytes, and other cells of the im-
mune and inflammatory system (Vega et al., 2003), but
their function in nonneural tissues is not as well under-
stood, though it may also entail cell-survival promotion
(Torcia et al., 1996). The Trk family shares a common
structure: the extracellular domain (ECD) comprises leu-
cine-rich motifs sandwiched between two cysteine clus-
ters, followed by two immunoglobulin (Ig)-like domains,
a single transmembrane domain, and an intracellularCell Hdomain (ICD) that contains a conserved tyrosine kinase
(see Figure 4D). The second Ig-like domain of TrkA,
TrkB, and TrkC reacts selectively with the neurotrophins
nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), and neurotrophin-3 (NT-3), respectively.
Neurotrophin engagement initiates receptor dimerization,
autophosphorylation, and activation of three main signal-
ing pathways, one of which, phosphatidylinositol (PI)
3-kinase/Akt protein kinase, is a foremost mediator of
Trk-induced cell survival (Huang and Reichardt, 2003;
Kaplan and Miller, 2000). Thus, it stands to reason that
microbial pathogens should greatly facilitate and prolong
parasitism if, while invading host cells, they were to bind
Trks and trigger survival and protection mechanisms
normally associated with neurotrophin engagement.
Trypanosoma cruzi, the agent of a chronic and incurable
illness (Chagas’ disease) that afflicts millions of people in
the Americas, is an obligate intracellular parasite that in-
vades various organs throughout the body. In the nervous
system, it inhabits Trk-expressing astrocytes, microglia,
Schwann cells, enteric glial cells, and neurons (Da Mata
et al., 2000; Rosenberg et al., 1991; Tafuri, 1970). Infection
of the gastrointestinal tract can almost completely
destroy the autonomous nervous system and cause meg-
acolon and megaesophagus (megaviscera) (Brener, 1973;
Ko¨berle, 1968). T. cruzi also invades Trk-expressing cells
in nonneural tissues such as keratinocytes and Langer-
hans cells (dendritic cells) in the skin (Nargis et al.,
2001), a site where transmission of Chagas’ disease starts
after a reduviid insect bite (Brener, 1973).
Recent studies showed that a T. cruzi protein with neur-
aminidase (Pereira, 1983) and sialyl-transferase (trans-
sialidase or TS) (Parodi et al., 1992; Schenkman et al.,
1992; Scudder et al., 1993) activities mimics NGF by
binding and activating TrkA; hence, TS is also known as
parasite-derived neurotrophic factor (PDNF) (Chuenkova
and Pereira, 2000; Chuenkova and PereiraPerrin, 2004,
2006). Given that PDNF/TS is readily shed into the extra-
cellular milieu (Prioli et al., 1991), we originally thought
that it operated as a diffusible exogenous molecule
facilitating neuroregenerative events in Chagas’ disease
(Chuenkova and Pereira, 2000). However, PDNF/TS is
also bound to the outer membrane of invasive T. cruzi
trypomastigotes through a glycosylphosphatidylinositol
(GPI) anchor (Prioli et al., 1991; Rosenberg et al., 1991)ost & Microbe 1, 251–261, June 2007 ª2007 Elsevier Inc. 251
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T. cruzi Invasion through TrkAFigure 1. Specific Interaction of T. cruzi
Trypomastigotes with Soluble TrkAECD
and Transmembrane TrkA
(A) Binding of TrkAECD to T. cruzi. Trypomasti-
gotes were incubated with the indicated
amounts (per ml) of TrkAECD or FGFRECD for
1 hr at 4C, centrifuged, resuspended in SDS,
and analyzed by immunoblotting with anti-
human IgG to identify T. cruzi-bound growth
factor receptor. Arrowheads indicate bands
corresponding to TrkAECD (closed arrowhead)
and FGFRECD (open arrowhead). Amount of
T. cruzi-bound receptors was estimated by
scanning densitometry and plotted using the
GraphPad software.
(B) Displacement of T. cruzi-bound TrkAECD by
NGF. TrkAECD was pulled down by T. cruzi as
described in (A) in the presence or absence of
NGF. TrkAECD binding to T. cruzi in the absence
of NGF was set as 100%.
(C) Displacement of T. cruzi-bound TrkAECD by
PDNF. Same protocol as in (B), except PDNF
and not NGF was included in the TrkAECD/
T.cruzimixtures.Results in (A)–(C)are represen-
tative data of three independent experiments.
(D) Visualization of T. cruzi adherence to PC12
cells. Trypomastigotes were labeled with Cell-
Tracker Red CMTPX and added to PC12WT
and PC12nnr5 cells for 30 min at 4C, and the
cell monolayers were gently washed to remove
unattached parasites, fixed with 4% parafor-
maldehyde, and visualized by fluorescence
(upper panels) and phase-contrast (lower
panels) microscopy. Scale bar, 10mm.
(E) Quantitation of TrkA-mediated adherence of T. cruzi to neuronal cells. Adherence assay performed exactly as in (D) except parasites were incubated
without () orwith TrkAECD (1 mg/ml) in the absence or presence ofNGF (3 mg/ml), 1 hr prior to addition to the cells. Parasites adhering to PC12cellswere
estimated by fluorescence microscopy. Results represent the average of two independent experiments.
Error bars indicate the standard error of the mean.and thus it is strategically located to directly interact with
host cell surface receptors such as TrkA. Here we report
that T. cruzi adhered to PC12 cells in a TrkA-dependent
manner and that it invaded neuronal and nonneuronal
cells through functional, but not through kinase-deficient,
TrkA. In synchrony with concepts of antiadhesion therapy
in infectious diseases (Sharon, 2006), an inhibitor of TrkA
kinase autophosphorylation specifically attenuated infec-
tion in a mouse model of acute Chagas’ disease, as did
passive administration of diffusible TrkAECD, presumably
by competing with transmembrane TrkA for TrkA-
dependent cellular invasion.
RESULTS
T. cruzi Adheres to PC12 Cells through
the TrkA Receptor
The rat pheochromocytoma PC12 cell line is widely used
in studies designed to understand mechanisms of NGF
binding to TrkA and resultant intracellular signaling cas-
cades. Therefore, we exploited the PC12 cell model to
find out whether TrkA is a cellular receptor for T. cruzi to
adhere to and invade host cells.
Intracellular microbial pathogens must first bind to sur-
face receptors as a prelude to entry, differentiation, and252 Cell Host & Microbe 1, 251–261, June 2007 ª2007 Elseviermultiplication inside host cells (Cossart and Sansonetti,
2004; Sibley, 2004; Smith and Helenius, 2004). To
determine whether TrkA mediates T. cruzi adhesion to
PC12 cells, we first ascertained whether trypomastigotes
(25 mm3 3 mm), the invasive stage of the parasite, inter-
act specifically with the neurotrophin RTK. For this, we
performed whole-cell pull-down assays in which parasites
were incubated with various concentrations of TrkAECD
fused to the Fc domain of human IgG at 4C for 1 hr
(to prevent receptor internalization). Figure 1A and the
Figure 1A inset show that TrkAECD-Fc, but not fibroblast
growth factor receptor (FGFRECD-Fc), bound to T. cruzi
in a dose-dependent manner. The negative result with
FGFRECD-Fc implied that the Fc fragment did not
appreciably contribute to TrkAECD-Fc binding to T. cruzi.
Preincubating TrkAECD-Fc with various amounts of en-
dogenous (NGF) (Figure 1B) or exogenous (PDNF/TS)
(Figure 1C) ligands effectively inhibited adsorption of the
recombinant receptor to the parasites, reinforcing the
conclusion that TrkAECD-Fc bound to T. cruzi specifically.
To find out if the parasites interact with transmembrane
TrkA, trypomastigotes were labeled with the fluorescent
dye CellTracker Red and added to wild-type PC12 cells
(PC12WT) and TrkA-deficient PC12 cells (PC12nnr5) (Loeb
and Greene, 1993) at 4C for 30 min to allow adhesion toInc.
Cell Host & Microbe
T. cruzi Invasion through TrkAFigure 2. TrkA-Dependent T. cruzi Invasion of Neuronal and Epithelial Cells
(A) PC12WT cells, TrkA null mutant PC12nnr5cells, and PC12nnr5 cells stably expressing human TrkA (PC12TrkA) were infected with T. cruzi and, after
2 days, fixed and stained with DAPI and with human chagasic serum followed by anti-human IgG-Alexa 594 to visualize host cell nuclei and intracel-
lular parasite, respectively, by fluorescence microscopy.
(B and C) PC12WT, PC12nnr5, and PC12TrkA cells were infected with the indicated concentration of T. cruzi for 2 hr, and the degree of infection was
estimated, after 2 days, by counting infected and noninfected cells (>300 cells) by phase-contrast microscopy after staining with Diff-Quik.
(D) Infection ratio of mink lung epithelial cells (Mv1Lu) stably transfected with human TrkA gene (Mv1LuTrkA) over cells transfected with empty vector
(Mv1LuEV) following a protocol analogous to the one for PC12 cells. Experiments were performed in triplicates and repeated at least three times with
similar results.
Error bars indicate the standard error of the mean.host cell plasma membrane with minimum cellular entry.
Adherent T. cruzi was readily ascertained by fluorescent
microscopy, which revealed a great preference (p <
0.0001) for PC12 cells expressing TrkA (PC12WT) com-
pared to the mutant cells (PC12nnr5) (Figures 1D and 1E).
Adsorption of TrkAECD-Fc (1 mg/ml) to trypomastigotes
(107/ml) in a ratio that produced strong binding of chimeric
receptor to the parasites (Figures 1A, 1B, and 1C) brought
down adherence to PC12 cells to a level analogous to that
of TrkA-minus nnr5 cells (p < 0.0001) (Figure 1E). Further-
more, TrkAECD-Fc interference in T. cruzi-PC12 cell adhe-
sion was, in turn, reversed by NGF (p < 0.001) (Figure 1E).
Therefore, these results supported the conclusion that
transmembrane TrkA mediates T. cruzi adhesion.
T. cruzi Exploits the TrkA Receptor to Invade
Neuronal and Engineered Epithelial Cells
Adhesion of microbes to surface receptors may or may
not conduce invasion into cells (Sharon, 2006; Smith and
Helenius, 2004), thus we sought to determine whether
TrkA-mediated adhesion leads to TrkA-dependent
invasion.Cell HMonolayers of PC12WT cells and PC12nnr5 cells infected
with trypomastigotes (30 parasites per cell, 37C) re-
vealed wild-type PC12 cells to be much more permissive
to T. cruzi than mutant PC12 cells (Figures 2A and 2B);
transfecting TrkA to the TrkA-deficient PC12nnr5 (Loeb
and Greene, 1993) cells restored wild-type cell infection
levels (Figures 2A and 2C).
Similarly, T. cruzi invaded mink lung epithelial Mv1Lu
cells, which normally do not express TrkA, about 4-fold
more efficiently in cells engineered to express wild-type
human TrkA (Mv1LuTrkA) (Figure 2D), which additionally
suggests TrkA to be a mediator of T. cruzi invasion. TrkA
expressed in the epithelial cells was biologically active,
as NGF activated phosphorylation of TrkA-dependent
transcription factor CREB in Mv1LuTrkA, but not in
empty-vector-transfected Mv1Lu (Figure S1 in the Sup-
plemental Data available with this article online), consis-
tent with earlier results by other investigators (Ip et al.,
1993).
To determine whether the TrkA-binding site on T. cruzi
mediates invasion, trypomastigotes were preincubated
with TrkAECD-Fc to block trypanosome-bound PDNF/TS,ost & Microbe 1, 251–261, June 2007 ª2007 Elsevier Inc. 253
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T. cruzi Invasion through TrkAFigure 3. Specific Inhibition of T. cruzi Invasion by TrkAECD and TrkA Ligands
(A) TrkAECD inhibits T. cruzi invasion of PC12 cells. T. cruzi trypomastigotes were incubated in DME medium for 1 hr without (vehicle medium) or with
control FGFRECD (1 mg), and TrkAECD (1 mg) without (TrkAECD) or with either 3 mgNGF (TrkAECD +NGF) or 12 mg PDNF (TrkAECD + PDNF). Parasites were
washed by centrifugation to remove unbound TrkAECD and allowed to infect PC12 cells for 2 hr. Infection in vehicle medium was set at 0% inhibition.
(B) TrkA ligands (NGF, PDNF, rPDNF, and NT-3), but not non-TrkA ligands (LIF, BDNF), inhibit infection of PC12 cells. Cells were treated with DME
medium without (vehicle) or with 100 ng/ml TrkA ligands and 100 ng/ml non-TrkA ligands for 30 min prior to the infection. Infection levels of vehicle-
treated cells were used to calculate percentage of inhibition.
(C) TrkA ligands do not inhibit residual infection in PC12nnr5 cells, as determined by a protocol similar to that in (B). Experiments in (A)–(C) were
repeated five times, and the results represent average of those five experiments.
Error bars indicate the standard error of the mean.washed to remove parasite-unbound receptors, and used
to infect PC12 cells. The results showed that TrkAECD-Fc,
but not control FGFRECD-Fc, inhibited T. cruzi invasion
and that the inhibition was reversed by loading the neuro-
trophin-binding site of TrkA with either endogenous (NGF)
or exogenous (PDNF/TS) ligands (Figure 3A).
To verify whether T. cruzi invasion depends on the inter-
action of the parasite with the neurotrophin-binding site
of TrkA, PC12 cells were preincubated for 30 min with
TrkA-binding ligands (NGF, NT-3, and PDNF isolated
from T. cruzi or from engineered bacteria) and with non-
TrkA-binding ligands (leukemia inhibitory factor [LIF] and
BDNF). The results showed that all TrkA ligands inhibited
T. cruzi infection of PC12WT cells (Figure 3B), but not of
TrkA-deficient PC12nnr5 cells (Figure 3C), whereas non-
TrkA ligands did not alter T. cruzi invasion of PC12 cells
(Figure 3B). These results suggest that T. cruzi invasion
of PC12 cells depends on TrkA NGF-binding site occu-
pancy by the parasite PDNF/TS.
TrkA-Dependent T. cruzi Invasion Requires TrkA
Kinase Activity
Microbes do not automatically activate the surface recep-
tors that they use to invade cells, as exemplified by rabies
virus, which enters host cells by binding, but without acti-
vating, the panneurotrophin receptor p75NTR (Langevin
et al., 2002). Three distinct approaches suggest that
T. cruzi invasion through TrkA requires receptor tyrosine
kinase activity.
First, we determined whether T. cruzi triggers phos-
phorylation of TrkA and the TrkA-dependent survival sig-
naling pathways. The results showed that T. cruzi induced
TrkA autophosphorylation and activated MAPK and PI3K/
Akt kinase pathways in a TrkA-dependent manner (Fig-
ure S2), consistent with earlier results showing that soluble
PDNF/TS induces neurite outgrowth and cell survival254 Cell Host & Microbe 1, 251–261, June 2007 ª2007 Elsevier Ithrough TrkA activation (Chuenkova and PereiraPerrin,
2004).
Second, cells were treated with K252a (Berg et al.,
1992) and AG879 (Ohmichi et al., 1993) to see if these spe-
cific inhibitors of TrkA kinase autophosphorylation affect
T. cruzi invasion. The results showed that infecting
PC12WT cells sensitized with K252a (Figure 4A) and
AG879 (Figure 4C) reduced permissiveness to the level
of TrkA-deficient PC12nnr5 cells. Neither K252a nor
AG879 affected T. cruzi invasion of the TrkA-deficient cells
(Figures 4B and 4C), strongly suggesting that the two
compounds reduced infection by specifically inactivating
the TrkA kinase pathway of T. cruzi invasion. Furthermore,
screening various cell lines with TrkA kinase inhibitors
showed that only TrkA-expressing cells (PC12 cells and
dendritic cells) became less permissive to invasion upon
treatment with the TrkA kinase inhibitors (Table 1).
K252a-dependent inhibition of infection was not due to
toxicity on T. cruzi because preincubating parasites, but
not host cells, with the inhibitor did not affect invasion
(Figure S3). Treatment of PC12 cells with a specific tyro-
sine kinase inhibitor of insulin-like growth factor receptor
(IGF-1R) did not reduce T. cruzi infection (Figure 4D) (Gir-
nita et al., 2004; Zheng and Quirion, 2006), further under-
scoring specific action of K252 and AG879.
And third, a TrkA deletionmutant was expressed in neu-
ronal and epithelial cells to additionally find out if the
kinase domain of the receptor is required for TrkA-depen-
dent invasion. A TrkA derivative (TrkADICD) that contained
intact ECD and transmembrane domains but lacked most
of the intracellular kinase domain, including all residues
that become phosphorylated upon TrkA dimerization
(Figure 4E), was generated. Transfecting TrkA-deficient
PC12nnr5 cells with TrkADICD produced cells (PC12-
nnr5TrkA-DICD) that were poorly permissive, comparable
to cells transfected with empty vector (PC12-nnr5EV),nc.
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T. cruzi Invasion through TrkAFigure 4. TrkA Kinase Inhibitors and Deletion of TrkA Intracellular Domain Block T. cruzi Invasion
(A) K252a inhibits T. cruzi infection of PC12 cells. PC12WT cells were pretreated with 500 nMK252a for 1 hr prior to parasite addition. Infection assay is
similar to that described in the Figure 2 legend.
(B) K252a does not inhibit T. cruzi infection of PC12nnr5 cells; protocol is similar to that in (A).
(C) AG879 inhibits T. cruzi infection of PC12WT but not of PC12nnr5 cells. Protocol is similar to that in (A) and (B) except for the pretreatment with 50 mM
AG879.
(C) IGF1-R inhibitor does not block T. cruzi infection of PC12WT cells. Protocol is similar to that in (A) except that cells were pretreated with several
concentration of IGF-1R inhibitor and K252a.
(E) Diagram of wild-type TrkA (TrkAWT) and TrkA lacking intracellular domain (TrkADICD). Tyrosine residues that become phosphorylated upon TrkA
dimerization are missing in TrkADICD.
(F) NGF (10 ng/ml, 48 hr) does not stimulate neurite extension in PC12nnr5 cells transfected with TkADICD (PC12-nnr5TrkA-DICD) or empty vector (PC12-
nnr5EV), in contrast to the response of PC12nnr5 cells transfected with TrkAWT. After treatment, cells were fixed and stained with anti-neurofilament-
200 antibody and Alexa-conjugated secondary antibody. Scale bar, 10mm.
(G) TrkAWT, but not TrkADICD, rescues T. cruzi invasiveness in TrkA null PC12nnr5 cells. Infection assays are similar to the protocol in (A)–(C), which
show PC12-nnr5TrkA-WT cells supporting T. cruzi infection as well as PC12WT cells, in contrast to equally poorly permissive PC12-nnr5TrkA-DICD cells
and PC12nnr5-EV cells.
(H) TrkAWT, but not TrkADICD, enhances T. cruzi invasion of mink lung epithelial cells (Mv1Lu). Mv1LuTrkA-WT, Mv1LuTrkA-DICD, and Mv1LuEV cells were
infected with the indicated concentrations of T. cruzi. Results were plotted as the ratio of Mv1LuTrkA-WT and Mv1LuTrkA-DICD over Mv1LuEV.
The experiments in (A)–(D), (G), and (H) were repeated three times. The results are representative of one experiment of triplicate samples. Error bars
indicate the standard error of the mean.both in contrast to the rescue produced by TrkAWT in
PC12-nnr5TrkA-WT cells (Figure 4G). The rescue in invasion
produced by TrkAWT, but not TrkADICD, could not be ex-
plained by low expression of the kinase-deficient con-Cell Hstructs because TrkADICD and TrkAWT gene products
were expressed at similar levels (Figure S4). In agreement
with the expectation that TrkADICD is devoid of kinase ac-
tivity, PC12-nnr5TrkA-DICD cells did not extend neurites inost & Microbe 1, 251–261, June 2007 ª2007 Elsevier Inc. 255
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T. cruzi Invasion through TrkATable 1. Selective Inhibition of T. cruzi Invasion by TrkA Kinase Inhibitors
Cell Type
TrkA







Dendritic cellsy (primary culture) + 11.9 ± 3.2 5.6 ± 1.7 0.008* 52.94
PC12WT (neuronal cell line) + 14.6 ± 0.9 7.8 ± 2.3 0.02* 46.70
Smooth muscle cells (primary culture)  57.0 ± 1.6 53.9 ± 13.4 ns 5.57
L6E9 (skeletal muscle cell line)  39.4 ± 8.0 39.8 ± 4.1 ns 0.96
Schwann (glial cell line)  47.0 ± 12.6 44.7 ± 7.5 ns 4.99
PC12nnr5 (neuronal cell line)  4.3 ± 0.1 4.7 ± 1.4 ns 10
aCell monolayers were treated with vehicle medium (DMEM + 0.001% DMSO) or TrkA inhibitor (500 nM K252a for neuronal cells,
smooth and skeletal muscle cells, and glial cells, and 10 mMTrkA inhibitor for dendritic cells [y]) for 1 hr prior to infection with 53 106
T.cruzi/ml. After 2 days, cell were fixed and stained with Diff-Quick to visualize intracellular parasites. + and  denote expression
and absence of TrkA receptor, respectively.
b p value was calculated based on paired t test. *Statistically significant infection inhibition; ns, not statistically significant.response to NGF, in contrast to PC12-nnr5TrkA-WT
cells (Figure 4F). Furthermore, TrkAWT-transfected
Mv1Lu (Mv1LuTrkA-WT) became 4- to 5-fold more permis-
sive to T. cruzi than TrkADICD-transfected Mv1Lu
(Mv1LuTrkA-DICD) (Figure 4H), further supporting the con-
clusion that the kinase domain of TrkA is important for
T. cruzi invasion. Preliminary experiments showed that
Mv1Lu transfectants expressed TrkAWT and TrkADICD pro-
teins at similar levels (data not shown), excluding the pos-
sibility that Mv1LuTrkA-DICD cells were poor T. cruzi hosts
due to low expression of TrkADICD compared to TrkAWT.
Competitive Inhibitors of NGF-TrkA Interaction
Attenuate T. cruzi Infection in Experimental
Chagas’ Disease
Chagas’ disease is mostly transmitted to man after the
bite of reduviid insects on the skin, where resident nerves
and TrkA-expressing cells (such as mast cells, keratino-
cytes, and dendritic cells) upregulate TrkA expression
after injury (Pincelli, 2000; Shu and Mendell, 1999). While
some parasites may immediately leave the bite site,
many remain at the inoculation site and invade local host
cells (Schuster and Schaub, 2000). To find out whether
T. cruzi exploits the TrkA pathway to infect cells in subcu-
taneous tissues in vivo, we inoculated TrkAECD-Fc/T. cruzi
complex into the footpads of mice in a protocol meant to
mimic the inhibition of adhesion and invasion brought by
the chimeric receptor-parasite complex in vitro (Figures
1E and 3A, respectively). On days 8, 11, and 14 postinoc-
ulation, mice infected with TrkAECD-Fc-trypomastigotes
exhibited parasitemia 81%, 80%, and 53% lower than
mice inoculated with control T. cruzi adsorbedwith vehicle
medium or control receptor FGFRECD-Fc (Figure 5A and
inset).
One likely explanation for these in vivo results is that
binding of TrkAECD-Fc to trypomastigotes blocked para-
site recognition of transmembrane TrkA. A corollary to
this hypothesis is that addition of NGF to TrkAECD-Fc
should inhibit receptor binding to the parasites and re-256 Cell Host & Microbe 1, 251–261, June 2007 ª2007 Elsevierverse the blockade of parasite recognition of transmem-
brane TrkA in vivo, which was observed experimentally
(Figure 5B and inset).
Given that TrkA-dependent T. cruzi invasion of cells
in vitro requires tyrosine kinase activity of the receptor,
we also sought to determine whether this would be the
case for infection in vivo. First we sensitized footpads of
mice with K252a (11.7 mg/kg body weight) to inhibit TrkA
tyrosine kinase of permissive host cells in situ, followed
by inoculation of T. cruzi in the same site 1 hr later. Priming
with K252a at 11.7 mg/kg body weight was based on pre-
liminary dose-response experiments that showed this
dosage to optimally inhibit parasitemia (data not shown).
Measurement of tissue parasitism by real-time PCR (Cum-
mings and Tarleton, 2003) in the inoculation site 3 and
10 days later, and parasitemia at multiple days thereafter,
showed that K252a significantly reduced parasite load in
the inoculation site (Figures 6A and 6B) and in the blood
(parasitemia) (Figure 6C). Such reduced parasite load
was reflected in the decreased inflammatory response in
histological slices of the inoculation site 10 days after in-
fection (Figures 6E and 6F). That K252a attenuated infec-
tion inmice by inhibiting TrkA kinase activity of susceptible
cells in the inoculation site was validated by the results of
two other experiments. Here, we inoculated parasites in
a footpad distinct from the one primed with K252a or in
the same footpad sensitized with a tyrosine kinase inhibi-
tor specific for a growth factor receptor unrelated to TrkA
(IGF-1R). K252a did not reduce parasitemia when injected
into a site far away from the T. cruzi inoculation site (Fig-
ure S5), nor did the IGF-1R kinase inhibitor administered
in the same site as the trypanosomes (Figure 6D).
DISCUSSION
During prenatal development and adulthood, NGF medi-
ates proliferation, differentiation, and survival of neuronal
(Bibel and Barde, 2000; Huang and Reichardt, 2003)
and nonneuronal (muscle, astrocytes, monocytes, andInc.
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T. cruzi Invasion through TrkAFigure 5. Specific Inhibition of T. cruzi Infection In Vivo by Soluble TrkAECD
(A) TrkAECD, but not FGFRECD, reduces parasitemia in a murine model of Chagas’ disease. Trypomastigotes (2 3 106/ml) were incubated with DME
medium without (vehicle medium) or with TrkAECD, FGFRECD (1 mg/ml, 1 hr), washed by centrifugation to remove receptor unbound to parasites, and
inoculated (3 3 103/mouse) subcutaneously in the mice footpads. Parasitemia was monitored every 3 days for the indicated times. Inset shows the
degree of inhibition by TrkAECD (but not FGFRECD).
(B) NGF reverses the infection-inhibition action of TrkAECD. Protocol is similar to that in (A) except parasites were incubated for 1 hr with vehicle me-
dium without or with TrkAECD (1 mg/ml), TrkAECD (1 mg/ml) + NGF (3 mg/ml), washed by centrifugation, and inoculated into mice footpads. Inset shows
the degree of inhibition of parasitemia produced by TrkAECD and TrkAECD + NGF relative to control vehicle medium (dotted line). Experiments were
repeated twice with similar results.
Error bars indicate the standard error of the mean.dendritic) cells through the activation of tyrosine kinase re-
ceptor TrkA (Hutton and Perez-Polo, 1995; Rende et al.,
2000; Vega et al., 2003). NGF binding to TrkA also induces
receptor endocytosis and retrograde transport of signal-
ing endosomes (Huang and Reichardt, 2003; Kaplan and
Miller, 2000). Thus, if pathogenic microbes were to exploit
a neurotrophic survival receptor such as TrkA to access
the host cell intracellular milieu, one would expect such
a type of invasion to stimulate survival and metabolism
of the infected cells.
The results presented here show that the intracellular
protozoa parasite T. cruzi adheres to and invades PC12
cells through the recognition of TrkA, and that such recog-
nition triggers TrkA-dependent MAPK and PI3K/Akt ki-
nase signaling. Blocking TrkA activation in neuronal
(PC12) and nonneuronal (dendritic) cells by pharmacolog-
ical and genetic means greatly reduced T. cruzi invasion.
Conversely, forced expression of wild-type TrkA, but not
kinase-deficient TrkA, in a cell line naturally resistant to
T. cruzi (mink lung epithelial Mv1Lu cells) increased inva-
sion by 4-fold. Most interesting, interfering with the
T. cruzi/TrkA crosstalk either with a TrkA autophosphory-
lation inhibitor—K252a—or an NGF antagonist—soluble
ectodomain of TrkA—profoundly attenuated tissue para-
sitism, parasitemia, and inflammation in an animal model
of Chagas’ disease. Therefore, our findings support the
novel concept that a survival receptor—TrkA—tradition-
ally associated with development and repair of the ner-
vous system, functions as a vehicle for invasion by the in-
tracellular pathogen T. cruzi. Activated TrkA-dependent
survival pathways, whether by extracellular T. cruzi,
T. cruzi product PDNF/TS, or NGF, can last at least 2–3
days (Chuenkova and Pereira, 2000; Chuenkova et al.,
2001; Chuenkova and PereiraPerrin, 2004). Such durableCell Hresponse is consistent with the idea of invasion receptor
TrkA prolonging the life span of infected cells, which could
be further extended and/or augmented by intracellular
T. cruzi, as they, through mechanisms that have yet to
be elucidated, seem to inhibit apoptosis in Schwann cells
(Chuenkova et al., 2001) and cardiomyocytes (Aoki et al.,
2004; Petersen et al., 2006). And these cell-survival-pro-
moting actions would be particularly valuable in nondivid-
ing postmitotic cells such as neurons and heart muscle
cells.
The ligand that mediates TrkA-dependent T. cruzi inva-
sion is PNDF/TS, a protein widely studied for its ability to
catalyze the transfer of sialic acid from glycoconjugates
into the aqueous environment (neuraminidase activity)
(Pereira, 1983) and to b-galactosyl substrates (trans-siali-
dase activity) (Parodi et al., 1992; Schenkman et al., 1992;
Scudder et al., 1993). Although earlier work suggested
that these enzymatic activities may mediate T. cruzi inter-
action with epithelial and fibroblast cell lines (Ming et al.,
1993; Schenkman et al., 1993), subsequent findings did
not support such idea because a monoclonal antibody
against PDNF/TS, which completely inhibit trans-sialidase
activity, did not alter infection in vivo (Risso et al., 2006).
Similarly, TrkA-dependent entry of T. cruzi into cells may
not require the sialic-acid-binding site of PDNF/TS be-
cause a deletion mutant of the enzyme that inactivate
both neuraminidase and sialyl-transferase activities did,
nevertheless, promote neurite extension and survival of
PC12 cells to the same extent as enzymatically active
enzyme (Chuenkova and Pereira, 2000). Furthermore,
a PDNF/TS-based synthetic linear peptide of 21 amino
acids (Y21) reproduced neurotrophic properties of the in-
tact enzyme (Chuenkova and PereiraPerrin, 2005). That
trans-sialidase activity is dispensable for TrkA-dependentost & Microbe 1, 251–261, June 2007 ª2007 Elsevier Inc. 257
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T. cruzi Invasion through TrkAFigure 6. TrkA Kinase Inhibitor K252a
Reduces Parasite Tissue Load, Parasite-
mia, and Inflammation in Experimental
Chagas’ Disease
(A and B) K252a reduces tissue parasitism in
the inoculation site. Vehicle medium without
and with K252a (11.7 mg/kg of body weight)
was injected in the right footpad of C57BL/6
mice followed by inoculation of T. cruzi (3 3
103/ml) in the same site 1 hr later. Parasite
load at the inoculation site was quantified after
3 (A) and 10 days (B) by real-time PCR. Each
symbol represents a single infected mouse.
Note that the magnitude on the ordinate in (B)
is 103 greater than that in (A), reflecting para-
site growth with disease progression in early
acute disease.
(C) Kinetics of parasitemia were measured ev-
ery third day in groups of five mice infected
with T. cruzi using a protocol similar to that in
(A) and (B). Experiments were repeated three
times with similar results.
(D) Kinetics of parasitemia were measured ev-
ery 4 days in mice infected with T. cruzi using
protocol similar to that in (A) and (B) except
that mice were primed with IGF-1R inhibitor
(11 mg/kg of body weight).
(E and F) H&E-stained section of inoculation
site (right footpad) 10 days postinfection, re-
vealing reduced inflammation in the subcuta-
neous tissue infected with T. cruzi after priming
with K252a (F) compared with analogous site
sensitized with vehicle medium (G). Inflamma-
tory cells in both (E) and (F) consist of neutro-
phils, macrophages, and mononuclear cells.
Analysis is from two experiments with similar
results.
Error bars indicate the standard error of the
mean.invasionwas further validated by recently identified PDNF/
TS-modeled synthetic peptides that bind TrkA and po-
tently inhibit T. cruzi invasion of PC12 cells (M.d.M.-J.,
M. Chuenkova, and M.P., unpublished data). Thus,
PDNF/TS moonlights as a carbohydrate-binding enzyme
and as a neurotrophic factor, analogous to other moon-
lighting proteins like phosphoglucose isomerase, which
can function as carbohydrate-binding enzyme and as
a growth factor for neurons independently of carbohy-
drate-binding activity (Petsko and Ringe, 2004).
Schneider and Schweiger proposed more than a de-
cade ago that Trks mediate cell-cell interactions
(Schneider and Schweiger, 1991) based on the role played
by leucine-rich/cysteine-rich cassette of other receptors
such as microbial recognition of Toll-like receptors
(Kedzierski et al., 2004) and Leishmania infantum binding
to macrophages (Kedzierski et al., 2004). The results pre-
sented here provide experimental support, perhaps for the
first time, for TrkA-dependent cell-cell adhesion in a heter-258 Cell Host & Microbe 1, 251–261, June 2007 ª2007 Elsevierophilic (mammalian host cell and unicellular trypomano-
some) system (Figure 1). Such TrkA-dependent adhesion,
in turn, serves as a prelude for T. cruzi invasion of cells of
the nervous system and other tissues that express the
NGF receptor. It highlights one invasion mechanism
among various others that T. cruzi most certainly exploits
to infect a diverse range of distinct host cell types in
mammals.
Indeed, two other receptors, transforming growth factor
b receptor II (TGFb-RII) and bradykinin receptor, have
been proposed to mediate T. cruzi infection of cultured
mink lung epithelial Mv1Lu cells and human umbilical
vein endothelial cells, respectively (Ming et al., 1995;
Scharfstein et al., 2000). T. cruzi is not alone in taking
advantage of distinct receptors in the quest to invade
mammalian cells, for even a protozoan parasite—Leish-
mania—that inhabits a single cell type—macrophages—
uses at least three surface receptors (complement recep-
tors 1 and 3, and mannose/fucose receptor) (HandmanInc.
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also penetrate cells throughmultiple receptors as best ex-
emplified by HIV-1, which exploits at least four distinct
molecules (CD4, mannose binding C-type lectin, and che-
mokine receptors CXCR4 and CCR5) to infect cells (Smith
and Helenius, 2004). Nevertheless, TrkA is the first among
the Trk receptors and the other two major families of re-
ceptors for neurotrophic factors (neurokines and the
glial-cell-line-derived family of ligands) to be identified as
a mediator for the intracellular invasion of a microbe.
Given that neurotrophins can bind tomore than one Trk re-
ceptor, as in the case of NT-3, which can activate TrkA and
TrkC (Huang and Reichardt, 2003), it may be that PNDF
binds and mediates invasion not only through TrkA, but
also via TrkB and/or TrkC as well.
T. cruzi is believed to persist for many years inside my-
ocytes in the heart and gastrointestinal tract of chronic
chagasic patients (Brener, 1973). Adipocyte is also a likely
important T. cruzi reservoir, as parasite DNA can be de-
tected in adipose tissue as long as 300 days postinfection
(Combs et al., 2005). Given that most patients with acute
Chagas’ disease have T. cruzi in their cerebrospinal fluid
(Hoff et al., 1978) and that chronic chagasic patients im-
munosuppressed with HIV, drugs, or irradiation can reac-
tivate infection predominantly in their brains, including
striatum and other parts of the basal ganglia (Antunes
et al., 2002; Kohl et al., 1982; Rosemberg et al., 1992), it
may be that T. cruzi also remains dormant in cholinergic
basal forebrain and striatum, the only CNS site that con-
tains TrkA-expressing neurons (Steininger et al., 1993).
EXPERIMENTAL PROCEDURES
Parasites and Mammalian Cell Lines
The Silvio X-10/4 and Tulahuen strains of T. cruzi were propagated in
a human Schwann cell line as described previously (Chuenkova and
Pereira, 1995) and used for in vitro and in vivo assays, respectively.
Tulahuen strain was chosen for in vivo experiments because it pro-
duces readily detectable parasitemia and mortality, while Silvio strain
was used in the in vitro experiments because it grows robustly in cell
cultures. PC12WT and PC12nnr5 cells were gifts from Dr. Lloyd Green
(College of Physicians and Surgeons, Columbia University, NY), as
were PC12nnr5 cells stably expressing human TrkAWT used in
Figure 2A (Green et al., 1986; Loeb and Greene, 1993). The permanent
human Schwann cells cell line was used in a previous study (Chuen-
kova et al., 2001). Primary cultures of human smooth muscle cells
were a gift from Herbert Tanowitz (Albert Einstein College of Medicine,
Bronx, NY), and bone marrow-derived dendritic cells were a gift from
Kristin Stephan (Tufts Medical Center, Boston, MA). Mink lung epithe-
lial cells (Mv1Lu) and the myoblast cell line L6E9 were purchased from
ATCC.
Binding of TrkAECD to T. cruzi
Trypomastigotes (107/ml) were incubated with TrkAECD-Fc and
FGFRECD-Fc (R&D systems) in binding buffer (DMEM, 0.1% BSA) for
1 hr at 4C without or with putative competitors, washed four times
with binding buffer by centrifugation (1,5003 g, 10 min) to remove un-
bound receptor, and processed to quantitate bound receptor and
measure cell adhesion and invasion in vitro and in vivo. To ascertain
bound TrkAECD, parasites were resuspended in SDS sample buffer,
run on reducing SDS-PAGE (7.5%), transferred to nitrocellulose, and
probed with anti-human IgG peroxidase-labeled antibody (Promega)
and scanning densitometry (Bio-Rad laboratories). For cell adhesion,Cell Htrypomastigotes were labeled with fluorescent CellTracker Red
CMTPX (Molecular Probes) as recommended by the manufacturer
and added to PC12WT and PC12nnr5 cells for 30 min at 4C. Cell mono-
layers were washed four times in the cold, fixed in 4% paraformalde-
hyde for 15 min, washed in PBS three times, and analyzed by fluores-
cent microscopy.
T. cruzi Infection In Vitro
Cells were infected with T. cruzi (Silvio), and infection was visualized by
fluorescence or phase-contrast microscopy as previously described
(Chuenkova and PereiraPerrin, 2004). For inhibition experiments, cells
were preincubated for 30 min with PDNF or rPDNF purified by affinity
chromatography (Chuenkova and Pereira, 2000; Scudder et al., 1993),
NGF (Sigma-Aldrich), NT-3 (R&D Systems), LIF (Sigma-Aldrich), BDNF
(R&D systems), washed three times with DMEM, and infected with var-
ious concentration of T. cruzi. To test the effect of TrkA kinase inhibi-
tors (Calbiochem) on T. cruzi invasion, cells were preincubated for
1 hr with TrkA kinase inhibitor (10 mM, IC50 = 6 nM), K252a (500 nM,
IC50 = 3 nM), and AG879 (50 mM, IC50 = 10 mM), and IGF-1R inhibitor
(125 nM to 2 mM, IC50 = 1 nM) followed (without washing) by various
concentration of parasites for 2–3 hr.
Murine Model of Acute Chagas’ Disease and Real-Time
Quantitative PCR
Groups of five female C57BL/6 mice (Jackson Laboratory), 6–8 weeks
old, were injected subcutaneously into footpadwith 33 103 trypomas-
tigotes (Tulahuen) pretreated with FGFRECD-Fc or TrkAECD-Fc with or
without NGF. In some experiments, footpads were primed with vehicle
medium containing, or not, K252a (11.7 mg/kg of body weight) or IGF-
1R inhibitor (11 mg/kg of body weight) followed by T. cruzi inoculation in
the same site 1 hr later. Parasitemia was monitored every 3 days
(Chuenkova and Pereira, 1995). In some cases, footpads were col-
lected 3 and 10 days postinfection and tissue processed for hematox-
ylin and eosin staining or for quantification of parasite load by real-time
PCR (Cummings and Tarleton, 2003). Parasite load (relative amounts
of T. cruzi DNA per mouse DNA) was calculated by considering DNA
from uninfected mice as baseline and TNF (one-copy mouse gene)
as internal control. These experiments were approved by the Institu-
tional Animal Care and Use Committees (IACUC) of Tufts University-
New England Medical Center.
TrkA Constructs and Transfection Assays
Primers were designed to amplify TrkA cDNA encoding 796 amino
acids (full-length TrkAWT) (TrkA-1: 50-CCGCTCGAGATGCTGAG
AGGCCA-30 and TrkA-2: 50-CCGGAATTCCGCCCAGAACGTC 30) or
489 amino acids (truncated form that lacks kinase domain, or TrkADicd)
(TrkA-1 and TrkA-4: 50-CCGGAATTCCCTGTGGGTTCTC-30), for which
XhoI and EcoRI restriction sites were added to the 50 and 30 ends, re-
spectively. DNA was digested and ligated into the vector pEYFP-N1
(Clontech). Cells were transfected with Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s protocol. TrkA function was
tested by neurite outgrowth assay. Transfected PC12nnr5 cells were
treated with 10 ng/ml NGF in 0.5% FCS DMEM for 48 hr. Cells were
fixed in 4% paraformaldehyde, blocked in 5% BSA/PBS, and probed
with anti-neurofilament 200 (Sigma-Aldrich) followed by Alexa 594-
conjugated anti-rabbit IgG (Molecular Probes). Cells were analyzed
in a fluorescent microscope.
Supplemental Data
The Supplemental Data include five supplemental figures and can be
found with this article online at http://www.cellhostandmicrobe.com/
cgi/content/full/1/4/251/DC1/.
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